StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of Ayala Pharmaceuticals stock opened at $0.03 on Thursday. The business has a 50-day moving average price of $0.03 and a two-hundred day moving average price of $0.04. Ayala Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.78. The company has a market cap of $1.28 million, a P/E ratio of 0.00 and a beta of 1.68.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.